Address: South Wing, The Place, 1 Sandton Drive, Sandton, 2196
P O Box 784746, Sandton City, Sandton, 2146 ,South Africa
Tel: (+27-11) 783 0104
Web: http://www.drreddys.com/southafrica/
Dr. Reddy’s – South Africa operation is a wholly-owned subsidiary and one of the leading generics players in the country. With a dedicated field force it focuses on key therapeutic areas like Central Nervous System (CNS) and Primary Care.
The business performance in South Africa has been phenomenal in the last few years. The overall revenue as per FY10 has been at $9.4 million enlisting a 56% growth.
Its advantageous position is ensured through the presence of key contributors in its business model. The Research & Development capability helps the company ensure enhanced FTL Opportunities through non-infringing pdts and supports differentiation with products and competitors. Alongside, the in-house API manufacturing capabilities assures cost competitiveness in both private and tender based markets. The company’s Formulation capabilities and strong business development team ensures high-quality in-house product pipeline, shapes licensing strategy to maximize market share and enrich the product basket. All the more its committed filed force has also been promising in recent years while reaching to all segments of the market.
In the South Africa Generic market Dr. Reddy’s is ranked 18th in terms of Value and 20th in terms of volume (Source: IMS-SA IGMS, MAT, Nov. 2010).
Top-five products including Omez, Cifloc, Citraz, Amlate and DRL-Moxifloxacin contribute to over 50% of revenue.
Products cathegories:
Active Pharma Ingredients (API)
Custom Pharma Services (CPS)
Global Generics
New Chemical Entities (NCEs)
Differentiated Formulations
Biosimilars
Lenias Hwenda of Medicines for Africa examines the true impact of access to medicine initiatives in Africa, noting that many of the measures takes are often cosmetic and leave a…
Some of the top pharma news coming out of South Africa including Afrigen’s partnership with US National Institutes of Health (NIH), BioNTech’s efforts to bring an mRNA start-to-finish vaccine manufacturing network…
David Mukanga of the Bill and Melinda Gates Foundation gives an overview of the latest developments on the long road towards the creation of an African Medicines Agency and the…
Kelly Chibale, founder of the H3D Centre at the University of Cape Town and chairman & CEO of the H3D Foundation, outlines the rationale behind the establishment of these institutions,…
Medicines for Africa’s Lenias Hwenda highlights the vast gaps in COVID-19 vaccine access globally, especially in Africa where just six percent of the population has been vaccinated. Hwenda argues that…
Three months after the World Bank announced a EUR 600 million loan to South Africa’s Aspen Pharmacare, the African continent has received more good news as it seeks to increase…
In a notable first, following successful pilot immunisation programmes in Ghana, Kenya and Malawi, the World Health Organization (WHO) has recommended that the RTS,S malaria vaccine be rolled out across…
A roundup of the latest news from South African pharma, including Aspen’s impressive annual growth, Adcock Ingram’s full year profit drop, and Entos Pharma’s approval for Phase II clinical rials…
With Africa struggling to vaccinate its populations against COVID-19, the World Bank – along with government institutions from the USA, Germany, and France – has intervened to loan South African…
The latest from South African pharma, including President Ramaphosa’s blunt criticism of Big Pharma, Aspen’s reception of USD 700 million in international financial aid, Adcock Ingram’s disappointing results as fewer…
South African firm Aspen has inked a deal with Johnson & Johnson for the technical transfer and proposed commercial manufacture of their COVID-19 vaccine candidate, Ad26.COV2-S, boosting the company’s share…
As COVID-19 threatens to derail more than a decade’s worth of hard-won gains in the fight against malaria, Dr Benjamin Pretorius, managing director at ERADA Technology Alliance, warns that diversions…
See our Cookie Privacy Policy Here
